Pharma Focus Asia
Eppendorf Bioprocess Solutions

Novel Repotrectinib Therapeutic Option Discovered for Advanced Solid Tumors

Turning Point Therapeutics, Inc discovered novel repotrectinib, a leading drug candidate for the treatment of patients with advanced solid tumors having an NTRK gene fusion.

Repotrectinib is a therapeutic option for patients who have shown progress with 1 or 2 prior TRK TKIs after treatment, with or without prior chemotherapy and for patients who remain with no other options.

Repotrectinib consists of a small macrocyclic TKI of ROS1, TRK, and ALK. It is bind with the active kinase conformation and avoids steric interference from several clinically-resistant mutations.

Repotrectinib has also been granted an Orphan Drug designation in 2017. U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to lead drug candidate, repotrectinib for the treatment of TKI-pretreated advanced solid tumors.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEAMasterControl - Simplify CAPA in 7 StepsTFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile AppCPHI & PMEC China 2023Thermo Fisher Scientific - QualTrak3rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023Pharma Regulatory Conclave 2023